Wellstar patients who opt-in to use this free service can verify their identity with CLEAR before their appointment to simplify check-in once they arrive
Design of donecopride, a dual serotonin subtype 4 receptor agonist/acetylcholinesterase inhibitor with potential interest for Alzheimers disease treatment
The drug is being developed by Eli Lilly and Company, which has announced plans to progress retatrutide into Phase 3 clinical trials across multiple indications, including obesity, type 2 diabetes, and liver disease
Originally introduced for diabetes treatment, the drugs have rapidly expanded into obesity care and are now reshaping expectations for metabolic medicine
15, 30 June 2025, article 100188,
For semaglutide, the target dose for weight management is 2.4 mg weekly